CN106011288B - Huppert's disease diagnosis and treatment marker and its application - Google Patents
Huppert's disease diagnosis and treatment marker and its application Download PDFInfo
- Publication number
- CN106011288B CN106011288B CN201610601404.5A CN201610601404A CN106011288B CN 106011288 B CN106011288 B CN 106011288B CN 201610601404 A CN201610601404 A CN 201610601404A CN 106011288 B CN106011288 B CN 106011288B
- Authority
- CN
- China
- Prior art keywords
- eri3
- gene
- albumen
- expression
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to pharmaceutical technology field, the new application of a kind of ERI3 gene and its coding is disclosed.Research of the invention has shown that ERI3 gene and its coding albumen act not only as the molecular marker of diagnosis Huppert's disease, and can be used as the molecular target for the treatment of Huppert's disease.The studies above achievement of the invention is clinically to provide a kind of new diagnostic method and treatment means.
Description
Technical field
The present invention relates to diagnosing tumor, treatment, prediction prognosis fields, more particularly it relates to different to detect ERI3
It is often the diagnosing tumor of means, prediction method of prognosis；And inhibit the tumor therapeutic agent of ERI3 gene or protein.
Background technique
Huppert's disease (Multiple myeloma, MM) is to assemble marrow with malignant plasma cell and in blood or urine
A kind of middle malignant disease for m protein (M albumen) occur and being characterized.Clinical characters include easily hair infection, impaired renal function,
Anaemia, hypercalcinemia and osteolytic lesion.MM accounts for about the 10% of all malignant hematologic diseases, is apt to occur in the elderly, with Chinese people
Mouth aging, MM number of the infected have increased trend.It is now recognized that MM is the process being gradually in progress: many patients exist
The monoclonal globulin disease (MGUS) of interrogatory occurs for early stage, then progresses to MM, and some patientss finally develop as marrow dermoskeleton
Myeloma (plasma cell leukemia), in whole process Bone Marrow of Patients thick liquid cell with several genes mutation.Clinically, according to MM's
Some clinical parameters such as M albumen, β 2-MG carry out by stages, to take different remedy measures MM.Common staging scale has
Durie-Salmon (DS) Staging System and staging system system (ISS).ISS is by stages simple and easy to do, white according to β 2-MG and serum
Albumen two indices divide MM for I phase, II phase, III phase, and III phase conditions of patients and prognosis are worst.Present clinical treats each phase MM
Main means have hormone, alkyls drug, immunomodulator, protease inhibitors etc., these methods can be such that MM is alleviated,
But final inevitably recurrence, therefore have some new Clinics and Practices strategies to be developed.
Summary of the invention
It is multiple to diagnose by detection ERI3 gene or protein expression difference that one of the objects of the present invention is to provide one kind
The method of property myeloma.
The second object of the present invention is to provide a kind of multiple to predict by detection ERI3 gene or protein expression difference
The method of property myeloma prognosis.
The third object of the present invention is to provide one kind by inhibiting ERI3 gene or ERI3 albumen to treat multiple bone
The method of myeloma.
The fourth object of the present invention is to provide a kind of method for screening the drug for the treatment of Huppert's disease.
The fifth object of the present invention is to provide a kind of for treating the drug of Huppert's disease.
To achieve the goals above, present invention employs following technical solutions:
The present invention provides the products of detection ERI3 gene or ERI3 albumen in preparing Diagnosis of Multiple Myeloma tool
Purposes.
The present invention also provides the products of detection ERI3 gene or ERI3 albumen to predict Huppert's disease prognosis in preparation
Purposes in tool.
Further, the product of the detection ERI3 gene or ERI3 albumen includes the table for detecting ERI3 gene or ERI3 albumen
Up to horizontal product.The product includes the nucleic acid that can combine ERI3 gene or the substance (example that can combine ERI3 albumen
Such as antibody).The nucleic acid is able to detect the expression of ERI3 gene；The substance is able to detect the expression water of ERI3 albumen
It is flat.
The product of detection ERI3 gene of the invention can play its function based on the known method of nucleic acid molecules is used: such as
PCR, such as Southern hybridization, Northern hybridization, dot blot, fluorescence in situ hybridization (FISH), DNA microarray, ASO method, height
Flux microarray dataset etc..It can qualitatively, quantitatively or semi-quantitatively implement analysis using the product.
Include that nucleic acid in the said goods can be obtained by chemical synthesis, or by containing from biomaterial preparation
It is expected that the gene of nucleic acid, then using primer amplification designed for amplification expectation nucleic acid, it is obtained.
Further, the PCR method is known method, for example, ARMS (Amplification Refractory
Abruptly-changing system is not answered in Mutation System, amplification) method, RT-PCR (reverse transcriptase-PCR) method, nesting PCR method etc..Amplification
Nucleic acid can be by using dot blotting hybridization method, Surface Plasmon Resonance (SPR method), PCR-RFLP method, original position RT-PCR
Method, PCR-SSO (sequence specific oligonucleotide) method, PCR-SSP method, AMPFLP (amplifiable fragment length polymorphism) method,
MVR-PCR method and PCR-SSCP (single-strand conformation polymorphism) method detect.
Nucleic acid recited above includes the primer for expanding ERI3 gene, and the primer for including in product can be by passing through chemistry
Synthesis to prepare, by using those skilled in the art will know that method be suitably designed with reference to Given information, and passing through
Synthesis is learned to prepare.
In specific embodiments of the present invention, the nucleic acid is amplimer used in QPCR experiment, the primer
Sequence such as SEQ ID NO.1 (positive sequence) and SEQ ID NO.2 (reverse sequence) shown in.
Nucleic acid recited above may also include probe, and the probe can be prepared by chemical synthesis, by using this
The method that field technical staff knows appropriately is designed with reference to Given information, and is prepared by chemical synthesis, or can lead to
The gene for containing desired nucleic acid sequence from biomaterial preparation is crossed, and is expanded using the primer designed for amplification expectation nucleic acid sequence
Increase it to prepare.
The product of detection ERI3 albumen of the invention can play its function based on the known method of antibody is used: for example,
It may include ELISA, radioimmunoassay, immunohistochemical method, western blot etc..
The product of detection ERI3 albumen of the invention includes the antibody or its segment for specifically binding ERI3 albumen.It can make
With the antibody or its segment of any structure and size, immunoglobulin class, origin etc., as long as it combines target protein.This
The antibody or its segment for including in the testing product of invention can be monoclonal or polyclonal.Antibody fragment refers to reservation antibody
Peptide to the active antibody of the combination of antigen a part of (Partial Fragment) or containing antibody a part.Antibody fragment may include F
(ab′)2, Fab ', Fab, scFv (scFv), the Fv (dsFv) of disulphide bonding or its polymer, the area dimerization V it is (dual anti-
Body) or peptide containing CDR.The product of detection ERI3 albumen of the invention may include encoding antibody or Encoding Antibody Fragment
The isolated nucleic acid of amino acid sequence, the carrier comprising the nucleic acid, and carry the cell of the carrier.
Antibody can be obtained by the way that well known to a person skilled in the art methods.For example, preparation retains target all or in part
The mammalian cell expression vector of their polynucleotides of the polypeptide or integration coding of protein is as antigen.Exempted from using antigen
After epidemic disease animal, from the immune animal adaptive immune cell of process and myeloma cell is merged to obtain hybridoma.Then from hybridization
Tumor culture collects antibody.It can finally be implemented by using antibody of the ERI3 albumen for being used as antigen or part thereof to acquisition
Antigentic specificity purifies to obtain the monoclonal antibody for ERI3 albumen.Polyclonal antibody can be prepared as follows: with it is above
Identical antigen-immunized animal collects blood sample from by immune animal, serum is isolated from blood, then using upper
It states antigen and antigentic specificity purifying is implemented to serum.It can be by the antibody that is obtained with enzymatic treatment or by using the antibody of acquisition
Sequence information obtain antibody fragment.
The combination of marker and antibody or its segment can be implemented by method as commonly known in the art.For example, can
With following fluorescent marker protein or peptide: clean protein or peptide with phosphate buffer, addition DMSO, buffer, etc. standards
Standby dyestuff, then mixed solution, then at being placed at room temperature for 10 minutes.In addition, the labelling kit of commercialization can be used in label, it is all
Such as biotin labeling reagent box, such as biotin labeling reagent box-NH2, biotin labeling reagent box-SH
(DojindoLaboratories)；Alkali phosphatase enzyme mark kit such as alkali phosphatase enzyme mark kit-NH2, alkaline phosphorus
Sour enzyme labelling kit-SH (Dojindo Laboratories)；Peroxidase labelling kit such as peroxidase mark
Remember kit-NH2, peroxidase labelling kit-NH2 (Dojindo Laboratories)；Phycobniliprotein labelled reagent
Box such as phycobniliprotein labelling kit-NH2, phycobniliprotein labelling kit-SH, B- phycoerythrin labelling kit-NH2,
B- phycoerythrin labelling kit-SH, R-PE labelling kit-NH2, R-PE labelling kit SH
(DojindoLaboratories)；Fluorescent labeling reagent box such as fluorescein labelling kit-NH2, HiLyte Fluor (TM)
555 labelling kit-NH2,647 labelling kit-NH2 of HiLyte Fluor (TM) (Dojindo Laboratories)；And
DyLight 547 and DyLight647 (Techno Chemical Corp.), Zenon (TM), Alexa Fluor (TM) antibody
Labelling kit, Qdot (TM) antibody labeling kit (Invitrogen Corporation) and EZ- marker protein mark
Remember kit (Funakoshi Corporation).For correct labeling, suitable instrument can be used to detect by label
Antibody or its segment.
As the sample according to testing product of the invention, the tissue sample for example obtained from biopsy subject can be used
Or fluid.Sample is not particularly limited, as long as it is suitable for measurement of the invention；For example, it may include tissue, blood, blood plasma,
Serum, lymph, urine, serous cavity liquid, spinal fluid, synovia, aqueous humor, tear, saliva or its fraction or treated material
Material.
In specific embodiments of the present invention, tissue of the sample from subject.
In the present invention, " prognosis " refers to mistake of the tumor patient after inhibiting by surgical procedure etc. or alleviating tumour growth
Journey or result.In the present specification, prognosis can be by surgical procedure inhibit or alleviate tumour growth after 1,2,3,4,5,6,
7,8,9,10,15,20 years or more long when life state.Prognosis can be by checking biomarker, that is, ERI3 albumen or coding
The gene of ERI3 albumen is predicted.Prognosis prediction can be performed such that according to biomarker with or without or increasing or drop
It is low, determine that the prognosis of patient is good or bad, or determine the probability of good prognosis or poor prognosis.
In the present invention, " prognosis bona " refer to inhibit or alleviate for patient by surgical procedure etc. tumour growth it
Afterwards, patient's long-term (such as 3,5,6,7,8,9,10,15,20 years or longer) does not have critical condition.Alternatively, good prognosis can anticipate
Refer to and survives in such long-time, sent out again without transfer, without recurrence or nothing.For example, prognosis bona can mean at least 3 years or outstanding
It is to survive at least 5 years, preferably without transfer or recurrence.The most preferred state of prognosis bona is survival for a long time without disease.Such as
Used herein, " prognosis bona " can also include any such state, wherein it can be found that disease such as shifts, still
It is pernicious low and do not severely impact survival ability.
In the present invention, " prognosis mala " refers to that patient is short after inhibiting or alleviating tumour growth by surgical procedure etc.
Fatal condition occurs in period (such as 1,2,3,4,5 year or shorter).Alternatively, poor prognosis refers in such short-term extremely
It dies, shift, recur or sends out again.For example, poor prognosis can mean Preventive or dead at least 3 years or especially at least 5 years
It dies.
Prediction prognosis is referred to the process of prediction status of patient or as a result, is not meant to be predicted with 100% accuracy
The process or result of status of patient.Prediction prognosis refers to whether a possibility that determining certain processes or result increases, and simultaneously unexpectedly
Taste by determining a possibility that certain processes or result occurs or not compared with certain processes or result.Such as this
For invention, in the present invention in the raised patient of the level of ERI3 gene or ERI3 albumen, with the patient's phase for not showing this feature
Than more likely observing particular procedure or result.
Further, the product of the detection ERI3 gene or ERI3 albumen can be detection ERI3 gene or ERI3 albumen
Reagent is also possible to include kit, chip, test paper of the reagent etc., is also possible to measure using the high pass of the reagent
Sequence platform.
The present invention also provides it is a kind of diagnose Huppert's disease tool, the tool be able to detect ERI3 gene or
The expression of ERI3 albumen.The tool includes the nucleic acid that can combine ERI3 gene or the object that can combine ERI3 albumen
Matter (such as antibody).The nucleic acid is able to detect the expression of ERI3 gene；The substance is able to detect the table of ERI3 albumen
Up to level.
Further, the property of the nucleic acid and the substance is the same as noted earlier.
Further, the tool of the diagnosis Huppert's disease includes but is not limited to chip, kit, test paper or high pass
Measure microarray dataset；High-flux sequence platform is a kind of tool of special diagnosis Huppert's disease, with high-flux sequence skill
The development of art will become very easily work to the building of the gene expression profile of a people.By comparison Disease and just
The gene expression profile of ordinary person group, the exception for being easy to analyze which gene are related to disease.Therefore, know in high-flux sequence
The exception of the ERI3 gene purposes for also belonging to ERI3 gene related to Huppert's disease, equally protection scope of the present invention it
It is interior.
The present invention also provides a kind of tool for predicting Huppert's disease prognosis, the prediction Huppert's disease prognosis
Tool includes the nucleic acid that can combine ERI3 gene or the substance (such as antibody) that can combine ERI3 albumen.The nucleic acid energy
Enough detect the mRNA level in-site of ERI3 gene；The substance is able to detect the expression of ERI3 albumen.
Further, the property of the nucleic acid and the substance is the same as noted earlier.
Further, it is described prediction Huppert's disease prognosis tool include but is not limited to chip, kit, test paper or
High-flux sequence platform；High-flux sequence platform is a kind of tool of special diagnosis Huppert's disease, as high pass measures
The development of sequence technology will become very easily work to the building of the gene expression profile of a people.By comparing Disease
With the gene expression profile of normal population, the exception for being easy to analyze which gene is related to disease.Therefore, in high-flux sequence
The exception of the ERI3 gene purposes for also belonging to ERI3 gene related to Huppert's disease is known, equally in protection model of the invention
Within enclosing.
The number for the amino acid that anti-ERI3 antibody used in testing product of the invention, diagnostic tool or its segment are identified
Mesh is not particularly limited, as long as antibody can combine ERI3.When antibody is as therapeutic agent, preferably it can know
Amino acid not as much as possible, as long as it can inhibit ERI3 function.The number of antibody or the amino acid of its segment identification is at least
One, more preferably at least three.The immunoglobulin class of antibody is unrestricted, can be IgG, IgM, IgA, IgE, IgD or
IgY。
The present invention also provides a kind of diagnosis Huppert's disease or the method for predicting Huppert's disease prognosis, the sides
Method includes the following steps:
(1) sample of subject is obtained；
(2) expression of ERI3 gene or albumen in Samples subjects is detected；
(3) it associates whether by the expression of the ERI3 gene or albumen that measure with the illness of subject.
(4) compared with the control, the expression of ERI3 gene or albumen increases, then the subject is diagnosed as multiple bone
Myeloma or the subject are confirmed as prognosis mala.
The present invention also provides a kind for the treatment of method of Huppert's disease, the method includes inhibit ERI3 gene or
ERI3 albumen.
Further, the method includes inhibiting the expression of ERI3 gene, or expression or the inhibition ERI3 of inhibition ERI3 albumen
The activity of albumen.
The present invention also provides a kind of screening techniques of tumour medicine, can be by adding testing drug to tumour cell
Afterwards or in the expression water to some period measurement ERI3 gene or ERI3 albumen after tumor model animal application testing drug
It puts down to measure tumour medicine and improve the effect of tumor prognosis.More specifically, when ERI3 gene or the expression water of ERI3 albumen
It puts down when being reduced after addition or application testing drug or when restoring normal level, the drug may be selected as improvement tumor prognosis
Therapeutic agent.
The present invention also provides a kind of drugs of inhibitor containing ERI3 gene or ERI3 albumen.
The present invention also provides application of the above-mentioned inhibitor in the drug of preparation treatment Huppert's disease.
The inhibitor of ERI3 gene or ERI3 albumen of the invention is unrestricted, as long as can inhibit ERI3 or be related to
The expression or activity of the substance of the upstream ERI3 or downstream pathway, and for treating the effective drug of tumour.
Further, the inhibitor includes antisense nucleic acid, dsRNA, ribozyme, aptamer, ERI3 binding protein segment or antibody
Or its segment.
" antisense nucleic acid " refers to the nucleic acid containing the sequence complementary with the coding mRNA of ERI3.Antisense nucleic acid can by DNA,
RNA or both composition.Antisense nucleic acid does not need complementary with the mRNA100% of target ERI3.Antisense nucleic acid can contain Non-complementary bases,
As long as it being capable of specific hybrid under strict conditions.When antisense nucleic acid is introduced cell, it combines target polynucleotide
And inhibit transcription, RNA processing, translation or stability.In addition to antisense polynucleotides, antisense nucleic acid further includes polynucleotides simulation
Object, it contains by the main chain of modification and 3 ' and 5 ' end parts.Such antisense nucleic acid can be according to ERI3 sequence information come just
It generates when design and using well known to a person skilled in the art methods.
" dsRNA " refers to containing duplex-RNA constructs, by RNA interference (RNAi) come the RNA of inhibition of gene expression, including
SiRNA (short interfering rna) and shRNA (short hairpin RNA).DsRNA does not need the homology for having 100% with target-gene sequence,
As long as it can inhibit expression of target gene.In order to stabilize or other purposes, a part of dsRNA can be substituted with DNA.
Preferably, siRNA is the double-stranded RNA of 21-23 base.SiRNA can by well known to a person skilled in the art method come
Preparation, such as by chemical synthesis or as the analog of naturally occurring RNA.ShRNA is with hair clip corner (hairpin
Turn) the Short interfering RNA of structure.ShRNA can be prepared by the way that well known to a person skilled in the art methods, such as be closed by chemistry
Cell and DNA is expressed at or by introducing the DNA for encoding shRNA.
" ribozyme " refers to the RNA with catalytic activity, it can cut, paste, insertion and transfer RNA.The structure of ribozyme can
To include tup, hair clip etc..
" aptamer " refers to the nucleic acid in conjunction with something such as protein.Aptamer can be RNA or DNA.The form of nucleic acid can be with
It is double-strand or single-stranded.The infinite in length system of aptamer, as long as it can specifically bind target molecule, can by such as 10 to
200 nucleotide, preferably 10 to 100 nucleotide, more preferable 15 to 80 nucleotide, even more preferably 15 to 50 nucleosides
Acid composition.Aptamer can be used that well known to a person skilled in the art methods to select.For example, (index can be passed through using SELEX
The phyletic evolution for the ligand that formula enrichment carries out).
" the protein-bonded segment of ERI3 " refers in conjunction with ERI3 and inhibition ERI3 implements the segment of the protein of original function.
Drug of the invention can be used as medicine and be administered alone or apply together with other medicines.It can be with medicine of the invention
The other medicines that object is applied together are unrestricted, as long as it does not damage therapeutic or preventive medicine effect of the invention i.e.
It can, it is preferred that the drug for treating or preventing tumour may include such as alkylating agent, such as ifosfamide, ring phosphinylidyne
Amine, Dacarbazine, Temozolomide, Nimustine, busulfan, procarbazine, melphalan and Ranimustine；Antimetabolite, such as
Enocitabine, capecitabine, Carmofur, Cladribine, gemcitabine, cytarabine, cytarabine octadecyl phosphate
(cytarabine ocfosfate), Tegafur, tegafur-Uracil, Tegafur gimeracil oteracil potassium, deoxidation fluorine urine
Glycosides, hydroxycarbamide, fluorouracil, fludarabine, pemetrexed, Pentostatin, mercaptopurine and methotrexate (MTX)；Plant alkaloid, it is all
As Irinotecan, Etoposide, Sobuzoxane, docetaxel, nogitecan, Palmer altruism, vinorelbine, eldisine and
Vincaleukoblastinum；Antitumor antibiotic, such as actinomycin D, Aclarubicin, Amrubicin, idarubicin, epirubicin, Zinostatin
Stimalamer, daunorubicin, Doxorubicin, pirarubicin, bleomycin, Peplomycin, mitomycin C and mitoxantrone；
Drug based on platinum, such as oxaliplatin, carboplatin, cis-platinum and Nedaplatin；Hormonal medicaments, such as Anastrozole, Exemestane,
Estramustine, ethinyloestradiol, chlormadinone, Goserelin, tamoxifen, dexamethasone, Toremifene, Bicalutamide, Flutamide,
Prednisolone, Fosfestrol, mitotane, methyltestosterone, Medroxyprogesterone, Mepitiostane, Leuprorelin and Letrozole；Biological respinse modification
Agent, such as interferon-' alpha ', interferon beta, interferon gamma, interleukin, ubenimex, dry BCG and lentinan；With molecular targeted medicine
Object, such as Imatinib (imatinib), Gefitinib (gefitinib), gemtuzumab, ozogamicin, Tamibarotene, song
Appropriate monoclonal antibody, Tretinoin, bortezomib (bortezomib) and Rituximab etc..
Drug of the invention can be prepared into various dosage forms as needed.Including but not limited to, percutaneous, mucous membrane, nose, buccal,
Tablet, solution, granule, patch, paste, capsule, aerosol or suppository sublingual or orally use.
The administration method of drug of the invention is unrestricted, as long as it can play desired therapeutic effect or preventive effect i.e.
Can, including but not limited to intravenously, in peritonaeum, intraocularly, intra-arterial, intrapulmonary is taken orally, in vesicle, intramuscular, intratracheally, subcutaneously
, local by pleura by skin, sucking, by mucous membrane, skin, stomach is intra-articular, intra-ventricle, rectum, vagina,
In skull, in urethra, in liver, in tumor.In some cases, it can systematically be administered.It is locally to be administered in some cases.
The dosage of drug of the invention is unrestricted, can as long as obtaining desired therapeutic effect or preventive effect
To carry out appropriate determination according to symptom, gender, age etc..Example can be used in the dosage of therapeutic agent or prophylactic agent of the invention
Such as the therapeutic effect of disease or preventive effect are determined as index.
In the context of the present invention, " diagnosis Huppert's disease " is both multiple including judging whether subject has suffered from
Property myeloma, also include judge subject with the presence or absence of suffer from Huppert's disease risk.
" treatment " used herein is covered treatment-related in such as mankind of the mammal with related disease or illness
Disease or morbid state, and include:
(1) prevent disease or morbid state occurs in mammals, especially when the mammal is susceptible in the disease
Diseased state, but when being not yet diagnosed with this morbid state；
(2) inhibit disease or morbid state, that is, prevent its generation；Or
(3) alleviate disease or morbid state, even if disease or morbid state subside.
Term " treatment " is usually directed to treatment mankind or animal (for example, being applied by animal doctor), wherein can reach certain pre-
The therapeutic effect of phase, for example, inhibiting the development (including reduce development speed, stop development) of illness, improving illness and healing
Illness.It further include the treatment as precautionary measures (such as prevention).To not yet development be illness but have development be the illness endanger
The purposes of the patient of danger, is also included in term " treatment ".
The advantages of the present invention:
It is of the invention to have found a kind of molecular marker for diagnosing Huppert's disease, it can be using the molecular marker
Huppert's disease occur early stage can be used as judging, provide the survival rate of patient.
In addition, the present invention is capable of providing significant information to determine treatment side for patient by the prognosis of prediction patient
Case strategy.
The therapeutic agent of inhibitor including ERI3 gene or albumen of the invention can be used as new Huppert's disease
Therapeutic agent.
Detailed description of the invention
The influence that Fig. 1 display inhibits ERI3 gene expression to be proliferated multiple myeloma cells；
The influence that Fig. 2 display inhibits ERI3 protein function to be proliferated multiple myeloma cells；
Fig. 3 display inhibits influence of the ERI3 gene expression to multiple myeloma cells apoptosis；
The influence that Fig. 4 display inhibits ERI3 gene expression to invade multiple myeloma cells；
The influence that Fig. 5 display inhibits ERI3 gene expression to migrate multiple myeloma cells.
Specific embodiment
The present invention is described in further detail with reference to the accompanying drawings and examples.Following embodiment is merely to illustrate this
It invents rather than limits the scope of the invention.Test method without specific conditions in embodiment, usually according to conventional strip
Part, such as Sambrook et al., molecular cloning: laboratory manual (New York:Cold Spring HarborLaboratory
Press, 1989) condition described in, or according to the normal condition proposed by manufacturer.
1 genetic chip of embodiment screens difference expression gene
1, it draws materials:
Huppert's disease tissue: collecting MM Bone Marrow of Patients biopsy specimen totally 10 made a definite diagnosis, MM diagnostic criteria refering to " in
2011 revised edition of state's Huppert's disease diagnosis and treatment guide ".Male 5, female 5, the median age 59 years old in patient.
Normal bone marrow tissue: same time malnutritional anemia Bone Marrow of Patients biopsy specimen 10 are collected as control
Group, wherein male 5, female 5, the median age 53 years old.
2, the acquisition of RNA is organized
Total tissue RNA is extracted using Trizol one-step method.
3, the measurement of RNA purity and concentration
1 μ l of RNA solution, Instrument measuring OD260, OD280 are taken, RNA concentration is OD260 value × extension rate × 40/
1000, OD260/OD280 is calculated, ratio represents RNA solution purity is high in 1.7-2.0, -20 DEG C guarantors few containing impurity such as protein
It deposits.
4, RNA integrity detection
(1) 2 μ l RNA sample row, 1.5% agarose gel electrophoresis (80v, 15min) is taken；
(2) after separating zone, genefinder is dyed, and Zone electophoresis band is observed under blue light；
(3) as 28s/18s about 2:1, illustrate that RNA stablizes without degradation.
5, gene chip hybridization and scanning
After the linearized amplification of total serum IgE, cy3-UTP is marked, and the cRNAs after fluorescent marker uses RNEASY Mini Kit
Purifying, carries out fragmentation processing to the cRNAs marked with the RNAFragmentation Reagents of Amhion.Using beauty
People's full genome chip of expression spectrum (4x 44K gene) of Agilent company, state, 65 DEG C of hybridization 17h in chip hybridization furnace, then
Elution, dyeing, finally use Agilent DNA MicroarrayScanner scanner scanning.
6, chip data processing and analysis
Chip after hybridization imports data to analysis software, for two groups of ratios after chip scanner reads data point
Natural logrithm absolute value be greater than 2.0 or the gene less than 0.5 as difference expression gene.
7, statistical procedures
Data analysis is carried out using 13.0 statistical software of SPSS, group difference compares using one-way analysis of variance method, P <
0.05 difference has significant.
8, result
Chip results are shown, filter out 489 differential expressions between Huppert's disease tissue and normal bone marrow tissue altogether
Gene, wherein expression up-regulation gene 215, expression lower gene 274.
2 large sample of embodiment verifies the difference expression gene filtered out
Consideration yet there are no the gene conduct studied about the gene with Huppert's disease correlation in the prior art
Candidate gene, at the same consider gene sequencing as a result, selection ERI3 gene (its expression is raised in Huppert's disease tissue)
It is verified.
1, sample collection
50, Huppert's disease tissue, 60, normal bone marrow tissue are collected according to the method for embodiment 1.
2, it is verified in mRNA level in-site
2.1 extract tissue RNA
Step is the same as embodiment 1.
2.2 reverse transcription
Reverse transcription system totally 20 μ L, including 2 μ g/2 μ L, 50U/ μ L Rnasin of cell total rna, 1 μ L, 5 × reverse transcription are anti-
Answer 4 μ L, 10m M d NTP of buffer, 2 μ l, 50 μ g/mL random primer 2 μ L (promega), 200U/ μ L M-MLV reverse transcription
18 μ L of μ L, DEPC of enzyme.
37 DEG C are reacted 60 minutes, 95 DEG C of reactions of termination in 5 minutes.CDNA saves or carries out PCR amplification at -80 DEG C.
2.3PCR
Reaction system (is purchased from Tiangeng biochemical technology (Beijing) according to Real Master Mix (SYBR Green) kit
Co., Ltd) configuration, SYBR reaction system 10 μ L, 20 × SYBR solution of totally 25 μ L, 2.5 × Real Master Mix
1.25 μ L, 0.5 μ L of upstream primer, 0.5 μ L of downstream primer, 10.75 μ L, cDNA2 μ L of deionized water.Reaction condition is 94 DEG C
5min, 94 DEG C of 45s, 60 DEG C of 1min, 30 circulations, if blank control.
The fluorescence signal of preceding 10 circulations of PCR reaction adjusts baseline to suitable place, each fluorescence is bent as autofluorescent background signal
The recurring number in line and baseline crosspoint is Ct value.According to Δ C (t)=C (t)Target gene-C(t)β-actin, Δ Δ C (t)=2-ΔC(t), calculate target gene and β-actin relative expression quantity.
PCR primer sequence is as follows:
ERI3 gene primer sequence is as follows:
Upstream primer: 5 '-GTATTTACTTTCAAGAGCAAGA-3 ' (SEQ ID NO.1)；
Downstream primer: 5 '-TGGATATGGAGCAGAACT-3 ' (SEQ ID NO.2).
β-actin gene primer sequence is as follows:
Upstream primer: 5 '-CTGGCACCACACCTTCTACAAT-3 ' (SEQ ID NO.3)；
Downstream primer: 5 '-AATGTCACGCACGATTTCCCGC-3 ' (SEQ ID NO.4)
2.4 result
The results show that the mRNA level in-site of ERI3 gene is obvious in Huppert's disease tissue compared with normal bone marrow tissue
Up-regulation, relative expression quantity are 7.24 ± 0.94, and difference has statistical significance (P < 0.05).
3, it is verified on protein level
3.1 extract tissue total protein
The operation of protein extraction is carried out according to the specification of EpiQuik tissue/cell total protein extraction kit.
3.2Western blot detection
The protein quantification of extraction is subjected to SDS-PAGE electrophoresis, carry out later transferring film, closing, primary antibody is incubated for, secondary antibody is incubated for,
Colour developing.
3.3 statistical procedures
The gray value of protein band is analyzed using Image J software, using β-actin as internal reference, by ERI3 albumen
The gray value of band is normalized.Result data is indicated in a manner of mean+SD, is used
SPSS13.0 statistical software is next for statistical analysis, and difference between the two is examined using t, it is believed that has system as P < 0.05
Meter learns meaning.
3.4 result
The results show that ERI3 protein level dramatically increases in Huppert's disease tissue, phase compared with normal bone marrow tissue
It is 3.74 ± 0.63 to expression quantity, difference has statistical significance (P < 0.05).
Embodiment 3 inhibits ERI3 gene expression
1, siRNA design synthesis
For the siRNA sequence of ERI3:
SiRNA-ERI3:
Positive-sense strand is 5 '-UCUAGAAGUCCAUUCUUGGGC-3 ' (SEQ ID NO.5)
Antisense strand is 5 '-CCAAGAAUGGACUUCUAGACA-3 ' (SEQ ID NO.6)；
The above siRNA sequence and negative control siRNA sequence (siRNA-NC) are by the limited public affairs of Shanghai Ji Ma pharmaceutical technology
Department provides.
2, the culture and transfection of multiple myeloma cells
2.1 cell culture
RPMI8226 cell, which uses, contains 15% fetal calf serum (FBS), penicillin 100U/ml, 100 μ g/ml of streptomysin
1640 culture medium of RPMI be placed in 37 DEG C, 5%CO2, cultivate under saturated humidity environment.
2.2 cell transfecting
(1) it transfects first 24 hours, in 500 μ l nonreactive inoculation of medium 0.5-2*105A cell, cell fusion when transfection
Degree is 30-50%.Cell dissociation is mixed completely when bed board, cell accumulation is avoided to grow.
(2) with 50 μ l Opti-MEM dilution siRNA (the final concentration of 33nM of transfection cell, gently pressure-vaccum 3-5 times mixing.
(3) it is gently mixed by inversion transfection reagent, dilutes 1 μ l Lipofectamine2000 gently with 50 μ l Opti-MEM
Pressure-vaccum 3-5 times mixing, stands 5min at room temperature.
(4) transfection reagent and siRNA dilution are mixed, gently pressure-vaccum 3-5 times mixing, stands 20min at room temperature.
(5) transfection composite is added in 24 porocyte plates, 100 holes μ l/, and front and back jog cell plates are uniformly mixed.
(6) cell plates are placed in 37 DEG C, 5%CO2It is cultivated 18-48 hours in incubator.Interchangeable fresh culture after transfection 4-6 hours
Base.
3, the jamming effectiveness of detection siRNA is tested using QPCR
3.1 extraction cell total rnas are operated using conventional method.
3.2 reverse transcription
Step is the same as embodiment 2.
3.3QPCR
Step is the same as embodiment 2.
3.4 result
The results show that siRNA-ERI3 can effectively inhibit the expression of ERI3 gene, relatively compared with siRNA-NC group
Expression quantity is 0.36 ± 0.07, and difference has statistical significance (P < 0.05).
Measurement of the expression of embodiment 4ERI3 gene to multiple myeloma cells proliferative capacity
1, step:
The RPMI8226 cell of 48h will be transfected according to 2*103Cells/well is inoculated in 96 orifice plates,
According to the specification of Brd U cell proliferation reagent box (Chemicon International), cell Proliferation is measured
Rate.
2, result
As a result as shown in Figure 1, compared with transfecting siRNA-NC group, transfection siRNA-ERI3 group cell Proliferation is slow, difference
With statistical significance (P < 0.05).It is above-mentioned the experimental results showed that, ERI3 gene expression promotes multiple myeloma cells
Proliferation.
In 5 multiple myeloma cells antibody of embodiment and test
1, step:
Multiple myeloma cells RPMI8226 is inoculated in 96 porocyte culture plates, every hole 2*103A cells/well/
200 μ l, are handled as follows after cell is adherent:
Experimental group 1 (control group): unrelated monoclonal antibody (1:50) is added in multiple myeloma cells；
Experimental group 2: anti-human ERI3 monoclonal antibody (1:50) is added in multiple myeloma cells.
By cell in 37 DEG C, 5%CO2After incubator is incubated for 24 hours, according to Brd U cell proliferation reagent box
The specification of (Chemicon International) measures cell proliferation rate.
2, statistical method
Experiment is completed according to being repeated 3 times, and result data is indicated in a manner of mean+SD,
Using SPSS13.0 statistical software come for statistical analysis, difference between the two is examined using t, it is believed that is had as P < 0.05
It is statistically significant.
3, result
As a result as shown in Fig. 2, compared to control group, the group cells proliferation slowed down of anti-human ERI3 monoclonal antibody is added.Above-mentioned experiment
Multiple myeloma cells can be inhibited to be proliferated the result shows that inhibiting the function of ERI3 albumen.
Embodiment 6 measures influence of the ERI3 gene expression to Apoptosis
1, TUNEL method detects Apoptosis
(1) cell transfecting is carried out according to the step of embodiment 3；
(2) according to In situ cell apoptosis detection kit (Chemicon International) specification, copolymerization is utilized
Focusing microscope quantifies apoptotic cell；
(3) to TUNEL Positive Cell Counts.
2, statistical method:
Experiment is completed according to being repeated 3 times, and result data is indicated in a manner of mean+SD,
Using SPSS13.0 statistical software come for statistical analysis, difference between the two is examined using t, it is believed that is had as P < 0.05
It is statistically significant.
3, result:
As a result as shown in figure 3, comparing siRNA-NC groups of cells, transfection siRNA-ERI3 group Apoptosis obviously aggravates, poor
Different to have statistical significance (P < 0.05), the above results show ERI3 gene expression inhibition Apoptosis.
Embodiment 7 detects influence of the ERI3 gene expression to cell migration, invasion
1, Matrigel
1.1 experimental procedures:
(1) upper chamber is precoated with Matrigel (artificial basement membrane)；
(2) cell after planting transfection in upper chamber, inoculum density 5*104/ 100 μ l cells, in serum free medium
Middle culture 18h；
(3) cell is added in the RPMI-1640 culture medium of 0.1% FBS and cultivates 18h；
(4) 50 μ l Matrigel are drawn on ice；
(5) it is added in 150 μ l serum-free RPMI-1640 culture mediums of pre-cooling and mixes well；
(6) the 50 μ l of Matrigel mixed in (5) is taken respectively, is added to transwell upper chamber, is covered entire film；
(7) 37 DEG C, to overnight, make Matrigel polymerize plastic；
(8) cell is washed 2 times with serum-free RPMI-1640 culture medium, is added in the RPMI-1640 culture medium of serum-free,
To 100 μ l of total volume；
(9) (8) are uniformly added into Transwell upper chamber, between lower layer's culture solution and cell, avoid bubble；
(10) RPMI-1640 culture of the 500-600 μ l of room addition downwards containing 5%FBS, 37 DEG C, 5%CO2；
(11) liquid is exhausted after 48h, wipes the cell not penetrated, move to 100% methanol of cell of the lower surface of film
Fixed 30min, PBS are washed 2 times；
(12) 0.2% violet staining upper chamber 30min, PBS wash away uncalled crystal purple；
(13) it is counted under inverted microscope.
1.2 results:
Experimental result such as Fig. 4 is shown, compared with transfecting siRNA-NC group, transfection siRNA-ERI3 group cell invasion number is obvious
It reduces, difference has statistical significance (P < 0.05).
2, migration experiment
2.1 experimental procedure
(1) precoating Matrigel artificial basement membrane is not needed in upper chamber.Cell after planting transfection in upper chamber is inoculated with dense
Degree is (1*105The μ l cell of)/100, cultivates 18h in serum free medium；
(2) cell is added in the serum-free RPMI-1640 culture medium of 0.1% FBS and cultivates 18h；
(3) 50 μ l Matrigel are drawn with the pipette tips of pre-cooling on ice；
(4) it is added in 150 μ l serum-free RPMI-1640 culture mediums of pre-cooling and mixes well；
(5) it takes the 50 μ l of Matrigel mixed in (4) to be added to Transwell upper chamber respectively, covers entire film；
(6) 37 DEG C, to overnight, make Matrigel polymerize plastic；
(7) cell is washed 2 times with serum-free RPMI-1640 culture medium, is added in the RPMI-1640 culture medium of serum-free,
To 100 μ l of total volume；
(8) (7) are uniformly added into Transwell upper chamber, between lower layer's culture solution and cell, avoid bubble, downward room adds
Enter RPMI-1640 of the 500-600 μ l containing 10%FBS to cultivate, 37 DEG C, 5%CO2；
(9) liquid is exhausted after 48h, wipes the cell not penetrated, the cell for moving to the lower surface of film is solid with 100% methanol
Determine 30min, PBS is washed 2 times；
(10) 0.2% violet staining upper chamber 30min, PBS wash away uncalled crystal purple；
(11) it is counted under inverted microscope.
2.2 result
Experimental result such as Fig. 5 is shown, compared with transfecting siRNA-NC group, transfects siRNA-ERI3 groups of cells cell migration number
It significantly reduces, difference has statistical significance (P < 0.05).
The above results show that ERI3 gene expression is conducive to the migration and invasion of myeloma cell.
The explanation of above-described embodiment is only intended to understand method and its core concept of the invention.It should be pointed out that for this
For the those of ordinary skill in field, without departing from the principle of the present invention, several improvement can also be carried out to the present invention
And modification, these improvement and modification will also be fallen into the protection scope of the claims in the present invention.
Claims (9)
1. the product for detecting ERI3 gene or ERI3 albumen is pre- in preparation diagnosis Huppert's disease or prediction Huppert's disease
The application in tool afterwards.
2. application according to claim 1, which is characterized in that the detection ERI3 gene or the product of ERI3 albumen include
Detect the product of the expression of ERI3 gene or ERI3 albumen.
3. application according to claim 1 or 2, which is characterized in that the product includes can be in conjunction with the core of ERI3 gene
Acid can be in conjunction with the substance of ERI3 albumen；The nucleic acid is able to detect the expression of ERI3 gene；The substance can
Detect the expression of ERI3 albumen.
4. application according to claim 3, which is characterized in that the nucleic acid is specifically expanded used in real-time quantitative PCR
Increase the primer of ERI3 gene as shown in SEQ ID NO.1 and SEQ ID NO.2.
5. application according to claim 1, which is characterized in that the tool includes being able to detect ERI3 gene or ERI3 egg
The tool of white expression.
6. application according to claim 5, which is characterized in that the tool include can in conjunction with ERI3 gene nucleic acid or
Person can be in conjunction with the substance of ERI3 albumen；The nucleic acid is able to detect the expression of ERI3 gene；The substance is able to detect
The expression of ERI3 albumen.
7. application according to claim 6, which is characterized in that the nucleic acid is specifically expanded used in real-time quantitative PCR
Increase the primer of ERI3 gene as shown in SEQ ID NO.1 and SEQ ID NO.2.
Application of the inhibitor of 8.ERI3 gene or ERI3 albumen in the drug of preparation treatment Huppert's disease.
9. application according to claim 8, which is characterized in that the inhibitor is able to suppress ERI3 or is related to the upstream ERI3
Or the expression or activity of the substance of downstream pathway.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610601404.5A CN106011288B (en) | 2016-07-27 | 2016-07-27 | Huppert's disease diagnosis and treatment marker and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610601404.5A CN106011288B (en) | 2016-07-27 | 2016-07-27 | Huppert's disease diagnosis and treatment marker and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106011288A CN106011288A (en) | 2016-10-12 |
| CN106011288B true CN106011288B (en) | 2019-09-27 |
Family
ID=57115407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610601404.5A Active CN106011288B (en) | 2016-07-27 | 2016-07-27 | Huppert's disease diagnosis and treatment marker and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106011288B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106868197B (en) * | 2017-04-24 | 2019-07-05 | 刘志国 | Application of the gene marker in Huppert's disease |
| CN114277137B (en) * | 2020-03-30 | 2022-09-02 | 中国医学科学院肿瘤医院 | Application of exosomes ARPC5, HMGN1 and the like in lung cancer diagnosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105132575A (en) * | 2015-09-28 | 2015-12-09 | 北京泱深生物信息技术有限公司 | Molecular marker for osteoporosis and application of marker |
| CN105567851A (en) * | 2016-02-29 | 2016-05-11 | 北京泱深生物信息技术有限公司 | Diabetes-related molecular marker |
-
2016
- 2016-07-27 CN CN201610601404.5A patent/CN106011288B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105132575A (en) * | 2015-09-28 | 2015-12-09 | 北京泱深生物信息技术有限公司 | Molecular marker for osteoporosis and application of marker |
| CN105567851A (en) * | 2016-02-29 | 2016-05-11 | 北京泱深生物信息技术有限公司 | Diabetes-related molecular marker |
Non-Patent Citations (1)
| Title |
|---|
| Novel features of the XRN-family in Arabidopsis:Evidence that AtXRN4, one of several orthologs of nuclear Xrn2p/Rat1p functions in the cytoplasm.;J. P. Kastenmayer and P. J. Green;《PNAS》;20001205;第97卷(第25期);13985-13990 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106011288A (en) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102264916A (en) | Novel oncogene nrf2 | |
| CN105969901B (en) | Purposes of the MS4A6A as Huppert's disease diagnosis and treatment marker | |
| CN106222259B (en) | A kind of molecular marker of diagnosis and treatment Huppert's disease | |
| CN106011288B (en) | Huppert's disease diagnosis and treatment marker and its application | |
| CN105886659A (en) | DSTN gene and expression product thereof as diagnosis and treatment target of endometrial cancer | |
| CN105907879B (en) | Carcinoma of endometrium biomarker | |
| CN106191283B (en) | The diagnosis and treatment product of Huppert's disease biomarker | |
| CN106011260B (en) | A kind of molecular marker of diagnosis and treatment carcinoma of endometrium | |
| CN105969904B (en) | Huppert's disease biomarker | |
| CN106011289B (en) | The diagnosis and treatment target of LILRA2 gene and its expression product as Huppert's disease | |
| CN106244705B (en) | Application of the ERC1 in preparation diagnosis or treatment hypopharyngeal cancer tool | |
| CN106119358B (en) | The diagnosis and treatment product of carcinoma of endometrium biomarker | |
| CN106011291B (en) | A kind of molecular marker of diagnosis and treatment hypopharyngeal cancer | |
| CN105886660A (en) | Application of UHRF1 (ubiquitin-like, containing PHD and RING finger domains, 1) as endometrial cancer diagnosis and treatment marker | |
| CN106381329B (en) | The diagnosis and treatment target of C18orf8 gene and its expression product as hypopharyngeal cancer | |
| CN106947820A (en) | Purposes of the VCAN in adenocarcinoma of colon diagnosis and treatment | |
| CN106119357B (en) | Application of the TNS11 in preparation diagnosis and treatment carcinoma of endometrium product | |
| CN106222257B (en) | Application of the IGSF6 in preparation diagnosis and treatment Huppert's disease product | |
| CN106119399B (en) | Purposes of the ZNF385C as hypopharyngeal cancer diagnosis and treatment marker | |
| CN106011286B (en) | Hypopharyngeal cancer diagnosis and treatment marker and its application | |
| CN106148531A (en) | Hypopharyngeal cancer biomarker | |
| CN105969903B (en) | The diagnosis and treatment product of hypopharyngeal cancer biomarker | |
| CN106048031B (en) | Application of the SYNM in preparation diagnosis or treatment carcinoma of endometrium tool | |
| CN106947819A (en) | Adenocarcinoma of colon diagnosis and treatment mark | |
| CN106011290A (en) | Application of RPL8 to preparation of tool for diagnosing or treating multiple myeloma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Room 1210, Building 3, Ronghua Xintai Building, 10 Ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing Applicant after: Beijing Yang Shen biology information technology company limited Address before: 100080 Beijing city Haidian District Shanyuan Street No. 1 cubic court building room 3103 Applicant before: Beijing Yang Shen biology information technology company limited |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211116 Address after: 266000 room 2503, Qianshan building, building D2, phase II, Qingdao International Innovation Park, No. 1, Keyuan Weiyi Road, Laoshan District, Qingdao, Shandong Patentee after: Qingdao Yangshen biomedical Co., Ltd Address before: Room 1210, building 3, Ronghua Xintai building, No. 10, Ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing 100176 Patentee before: Beijing Yangshen biological information technology Co., Ltd |
|
| TR01 | Transfer of patent right |